Clinical Trial Detail

NCT ID NCT03321630
Title A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.